GW Pharma has positive momentum as interim results beckon

Last night, GW pharma (GWP),  confirmed its interim results would be next Thursday (May 20th). It is likely that expectation of updates on the regulatory approval status of Sativex in the Europe has begun to move the stock and it is currently up around 5% to 126p to buy. In addition it is hoped that further news about the U.S. FDA application for cancer pain will be available. At 126p the stock is still below the level it reached in March when the last regulatory update was given and I am hoping that we will see a level much higher than this once Sativex has passed all the hurdles for the registration in Europe. The company were confident that the drug would be approved by end of Q2 i.e. June at the last major announcement.